<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127743">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01901575</url>
  </required_header>
  <id_info>
    <org_study_id>11-00800</org_study_id>
    <nct_id>NCT01901575</nct_id>
  </id_info>
  <brief_title>Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia</brief_title>
  <official_title>Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine effects of remifentanil conscious sedation in patients undergoing
      Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia
      and/or persistent frequent PVCs of non-ischemic origin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to determine the effects of remifentanil conscious sedation in
      patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic
      ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin.

      Remifentanil is an analgesic- synthetic opiate with an very short half life. It is rapidly
      broken down by enzymes in the blood and is ideally suited for continuous sedation. The
      effect is practically eliminated within 5 minutes after the intravenous sedation is stopped.

      You are being asked to participate in this study because you are already scheduled to
      undergo EP studies under the care of your cardiologist for the ablation of idiopathic
      ventricular tachycardia and/or persistent frequent PVCs of non-ischemic origin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Inhibition of idiopathic ventricular tachycardia</measure>
    <time_frame>during procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>observation of the anesthetic effect on the inhibition of the ventricular tachycardia in patients undergoing radio-frequency ablation of idiopathic ventricular tachycardia (RV0T)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Tachycardia, Ventricular</condition>
  <arm_group>
    <arm_group_label>Remifentanil IV PCA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <arm_group_label>Remifentanil IV PCA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo EP studies for the ablation of idiopathic ventricular
             tachycardia and/or persistent frequent PVCs of non-ischemic origin

          -  Patients between 18 and 65

          -  ASA 1-3

        Exclusion Criteria:

          -  ASA 4 and 5

          -  Age 18 and 65
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Misha Kogan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Garofalo NA, Teixeira-Neto FJ, Schwartz DS, Vailati Mdo C, Steagall PV. Effects of the opioid remifentanil on the arrhythmogenicity of epinephrine in halothane-anesthetized dogs. Can J Vet Res. 2008 Jul;72(4):362-6.</citation>
    <PMID>18783026</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 12, 2013</lastchanged_date>
  <firstreceived_date>April 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York University School of Medicine</investigator_affiliation>
    <investigator_full_name>Avrimin M Kogan, MD</investigator_full_name>
    <investigator_title>Clinical Assistant Professo</investigator_title>
  </responsible_party>
  <keyword>ideopathic ventricular tachycardia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
